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Aminopeptidase N (APN ⁄ CD13) is involved in tumor cell invasion and tumor
angiogenesis and is considered a promising therapeutic target in the treatment
of cancer. To develop a novel monoclonal antibody-based cancer therapy target-
ing APN ⁄ CD13, we established a fully humanized anti-APN ⁄ CD13 monoclonal
antibody, MT95-4. In vitro, MT95-4 inhibited APN ⁄CD13 enzymatic activity on the
tumor cell surface and blocked tumor cell invasion. B16 mouse melanoma cells
stably expressing human APN ⁄CD13 were also established and were inoculated
s.c. or injected i.v. into nude mice. We found that expression of human APN
⁄CD13 in murine melanoma cells increased the size of subcutaneous tumors,
extent of lung metastasis and degree of angiogenesis in the subcutaneous
tumors; these tumor-promoting and angiogenesis-promoting characteristics were
reduced by the i.p. administration of MT95-4. To further verify the specificity of
MT95-4 for neutralization of APN ⁄ CD13 activity, MT95-4 was administered into
NOD ⁄ SCID mice inoculated s.c. with H1299 or PC14 cells, which exhibit high
expression of APN ⁄ CD13, or with A549 cells, which exhibit weak expression of
APN ⁄CD13. MT95-4 reduced tumor growth and angiogenesis in mice bearing
H1299-derived and PC14-derived tumors, but not in mice bearing A549-derived
tumors. These results suggested that the antitumor and anti-angiogenic effects
of MT95-4 were dependent on APN ⁄CD13 expression in tumor cells. Given that
MT95-4 is the first fully humanized monoclonal antibody against APN ⁄ CD13,
MT95-4 should be recognized as a promising candidate for monoclonal antibody
therapy against tumors expressing APN ⁄CD13.
A minopeptidase N (APN ⁄CD13) is a type II membrane-bound glycoprotein that acts as a zinc-binding metallo-
protease.(1) APN ⁄CD13 consists of 967 amino acids with a
short N-terminal cytoplasmic domain, a single transmembrane
region, and a large extracellular C-terminal domain that
cleaves N-terminal amino acid residues from small peptides.(1–4)
APN ⁄CD13 is expressed by most cells of myeloid origin,
including monocytes, macrophages and granulocytes, and is
also abundantly expressed in the brush border of epithelial
cells of the small intestine and renal tubules, synaptic mem-
branes of the central nervous system, and endothelial cells.(5)
In hematopoietic cells, APN ⁄CD13 is considered a marker of
differentiation; however, its specific functions have not been
fully elucidated. While APN ⁄CD13 has been shown to play
roles in the final digestion of peptides in the small intestine
and in the degradation of neuropeptides in the synaptic mem-
brane, its function in proximal tubular epithelial cells is less
clear.(1–5) Moreover, although APN ⁄CD13 has been proposed
to be involved in many physiological processes, mice deficient
in the APN ⁄CD13 gene are reported to develop normally with-
out histological or physiological alterations.(6) Notably, APN
⁄CD13 has been reported to be expressed in various types of
tumor cells(5) and to play important roles in tumor growth by
promoting tumor cell invasion(7–9) and angiogenesis.(10–12)
Indeed, the expression of APN ⁄CD13 is associated with a poor
prognosis in patients with colon, pancreatic and lung can-
cers,(13–15) and high levels of circulating APN ⁄CD13 have
been recognized as an independent prognostic factor in patients
with non-small cell lung cancer.(16) Based on these data, APN
⁄CD13 can be regarded as a target molecule for cancer ther-
apy. In previous studies, bestatin (Ubenimex), an inhibitor of
APN ⁄CD13, aminopeptidase B and leucine aminopeptidase,
was shown to suppress tumor growth in xenograft tumor mod-
els.(17,18) Moreover, in a clinical trial, adjuvant bestatin therapy
prolonged survival in patients with resected stage I squamous
cell lung carcinoma.(19) These data support the potential and
feasibility of cancer therapy targeting APN ⁄CD13.
Previously, we established a murine monoclonal antibody
against APN ⁄CD13 (MH8-11) by immunizing mice with
HT1080 human fibrosarcoma cells; this monoclonal antibody
exhibited antitumor effects, inhibiting tumor cell invasion and
angiogenesis.(13) Therefore, we hypothesized that monoclonal
antibody therapy targeting APN ⁄CD13 would be useful as a
treatment for tumors exhibiting APN ⁄CD13 expression. There-
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fore, to promote the potential clinical application of our work,
we aimed to establish a fully humanized monoclonal antibody
for inhibition of APN ⁄CD13 activity. In the current study, we
raised fully humanized monoclonal antibodies by immuniza-
tion of KM mice, which produce humanized antibodies,(20)
with HT1080 cells and, from the resulting antibodies, we
selected a monoclonal antibody (named MT95-4) on the basis
of its ability to inhibit APN ⁄CD13 activity in vitro. To evalu-
ate the antitumor effects of MT95-4 in vivo, we established
subcutaneous tumor models and tail vein metastasis models
using B16-F1 melanoma cells transfected with human APN
⁄CD13 and human lung cancer cells, which exhibited high
expression of APN ⁄CD13, in immune-deficient mice. Tumor-
bearing mice were then treated with MT95-4, and the tumor
progression and angiogenesis were analyzed.
Materials and Methods
Cells and cell culture. HT1080, B16-F1 melanoma, H1299
and A549 cells were obtained from American Type Culture
Collection (ATCC; Manassas, VA, USA). PC14 cells were
obtained from Immuno-Biological Laboratories (Gunma,
Japan). HT1080, B16-F1, and A549 cells were cultured in
DMEM (Gibco, Grand Island, NY, USA), and H1299 and
PC14 cells were cultured in RPMI 1640 Medium (Gibco) sup-
plemented with 10% FBS and 1% penicillin-streptomycin. All
cells were incubated at 37°C in an atmosphere containing 5%
CO2.
A retroviral vector (pDON-5neoCD13; Takara Bio, Shiga,
Japan) containing APN ⁄CD13 cDNA and a control pDON-
5neo vector were transfected into B16-F1 melanoma cells
according to the manufacturer’s protocol. Transfectants resis-
tant to 1 mg ⁄mL G-418 (Promega, Madison, WI, USA) were
selected and maintained in DMEM with 10% FBS and 1 mg
⁄mL G-418. From these B16-F1 transfectants, one cell line that
expressed high levels of APN ⁄CD13 (APN-B16 cells) and
another cell line that did not express APN ⁄CD13 (control-B16
cells) were selected. The expression levels of APN ⁄CD13 were
determined by flow cytometry and real-time PCR.
Reagents and animals. Matrigel was purchased from BD Bio-
sciences (Bedford, MA, USA). KM mice were kindly provided
by Kyowa Hakko Kirin (Tokyo, Japan). Male BALB ⁄ c nude
mice and NOD ⁄SCID mice (6–8-weeks old) were purchased
from Charles River Laboratories (Wilmington, MA, USA).
Animals were maintained according to guidelines for the ethi-
cal use of animals in research at Hiroshima University.
Establishment of a fully humanized monoclonal antibody that
inhibited APN ⁄CD13 activity. Because the establishment of a
murine monoclonal antibody against APN ⁄CD13 had been suc-
cessful by immunizing Balb ⁄ c mice with HT1080 human fibro-
sarcoma cells,(13) KM mice, which lack endogenous genes
encoding the immunoglobulin (Ig) H and L j chains and
instead carry human chromosome 14 fragments containing the
entire human Ig H chain loci and the human j L chain seg-
ments,(20) were injected i.p. with HT1080 cells three times.
Three days after the last injection, spleen cells from the mice
were fused to SP2 ⁄O-AG14 myeloma cells (ATCC) to gener-
ate hybridomas. A clone that had an inhibitory effect on APN
⁄CD13 activity assessed by aminopeptidase assay was selected
(MT95-4).
Aminopeptidase assay. Cell-associated aminopeptidase activity
was assessed by measuring the amount of 7-amino-4-meth-
ylcoumarin (AMC) liberated from L-alanine-4-methylcoumarin-
7amide (Ala-MCA; Peptide Institute, Osaka, Japan), as previously
described.(8,9) A mixture containing 0.1 mM Ala-MCA,
5 9 103 HT1080 cells, and a raised antibody or human control
IgG (Sigma, St. Louis, MO, USA) suspended in 200 lL of
(a)
(b)
(c)
Fig. 1. Function of a fully humanized monoclonal antibody, MT95-4,
in vitro. (a) Evaluation of the specificity of MT95-4 by western blotting
analysis using cell lysates from HT1080 cells. (b) Effects of MT95-4 on
the aminopeptidase activity of HT1080 cells. The levels of AMC
released from Ala-MCA were measured. Data represent the mean
( SEM) of triplicate samples. *P < 0.05 versus the control. NS, not sig-
nificant. (c) Effects of MT95-4 on the invasion of HT1080 cells in a Ma-
trigel invasion assay. Data represent the mean ( SEM) of five wells.
***P < 0.001 versus the control.
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PBS was seeded into each well of a 96-well plate and incu-
bated for 2 h at 37°C in an atmosphere containing 5% CO2.
After incubation, 20 lL of 0.2 M EDTA was added to each
well to terminate the reaction, and the level of AMC was then
analyzed with a TriStar LB 941 Multimode microplate reader
(excitation, 355 nm; emission, 460 nm; Berthold Technologies,
Bad Wildbad, Germany).
Matrigel invasion assay. The invasive properties of tumor
cells were assessed using Matrigel invasion chambers (24-
well inserts, pore size: 8 lm [BD Biosciences]). Tumor cells
were resuspended in medium containing 0.1% FBS. Cell sus-
pensions with MT95-4 or control IgG were added to the
upper chamber at a density of 2.5 9 104 cells ⁄500 lL med-
ium ⁄well and incubated for 22 h at 37°C in an atmosphere
containing 5% CO2. The cells invading to the lower surface
of the membrane were stained with Diff-Quik stain after
removing noninvading cells with cotton swabs. Images were
captured using a microscope at a magnification of 200 9
(model BZ-9000; Keyence, Osaka, Japan), and the number of
invading cells was counted in five random microscopic fields
per well.
Flow cytometric analysis. FACS was performed to assess the
expression level of APN ⁄CD13 on the cell surface. The cells
were incubated for 30 min at 4°C with murine monoclonal
anti-APN ⁄CD13 antibodies (WM15; BD Biosciences) and iso-
type control. Cells were then washed with PBS and stained
with Alexa-Fluor-488-conjugated goat anti-mouse secondary
antibodies (Invitrogen, Carlsbad, CA, USA). The samples were
analyzed on a FACSCalibur flow cytometer (BD Biosciences),
and the data were analyzed using CELL Quest software (BD
Biosciences).
Quantitative real-time PCR. Total RNA was isolated using an
RNeasy Mini kit (Qiagen, Valencia, CA, USA). The isolated
total RNA was reverse transcribed into cDNA using a High
Capacity RNA-to-cDNA kit (Applied Biosystems, Framing-
ham, MA, USA) following the manufacturer’s instructions.
Quantitative real-time PCR was performed on an ABI Prism
7700 (Applied Biosystems) for detection and quantification of
human APN/CD13 using beta-actin as a control housekeeping
gene.
Western blot analysis. HT1080 cells were lysed with lysis
buffer containing 1% 3-[(3-cholamidopropyl)dimethylammo-
nio]-1-propanesulfonate. The soluble fraction of the cell lysate
was electrophoresed on 10% sodium dodecyl sulfate SDS-
PAGE and transferred electrophoretically to membranes.
The lower part of the membrane around 43 kDa was cut and
(a) (b)
(c) (d)
(e) (f)
Fig. 2. Effects of human APN ⁄ CD13 expression in
murine B16-F1 melanoma cells. (a) Expression levels
of human APN/CD13 mRNA in control-B16 and
APN-B16 cells were evaluated by quantitative real-
time PCR. (b) Expression levels of APN ⁄ CD13 on the
surface of control-B16 and APN-B16 cells were
assessed by flow cytometry. Data (a) represent the
mean ( SEM) of triplicate samples. ***P < 0.001.
(c) Comparison of the numbers of lung surface
nodules in the tail vein metastasis model between
control-B16 and APN-B16 cells. The numbers of
lung surface nodules in mice were counted 21 days
after injection of control-B16 and APN-B16 cells.
Each bar represents the mean number of nodules
for eight mice per group. *P < 0.05. (d) Comparison
of tumor volumes in a subcutaneous tumor model
for tumors derived from control-B16 and APN-B16
cells. The sizes of subcutaneous tumors were
measured twice a week for 2 weeks after
inoculation of control-B16 and APN-B16 cells. The
data represent the mean ( SEM) for eight mice
per group. *P < 0.05. (e) Evaluation of angiogenesis
in subcutaneous tumors derived from control-B16
and APN-B16 cells. The area containing CD31-
positive vessels was measured. Data represent the
means ( SEM) from eight mice per group.
**P < 0.01. (f) Immunohistochemical staining for
CD31 in a subcutaneous tumor. Scale bar, 100 lm.
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incubated overnight with rabbit anti-b-actin antibodies (4976S;
Cell Signaling Technology, Danvers, MA, USA). The remain-
ing section of each membrane was evenly divided into two
parts and incubated with rabbit anti-APN ⁄CD13 antibodies
(2972-1; Abcam, Cambridge, UK) or MT95-4. After washing,
the membranes were incubated with HRP-conjugated anti-rab-
bit or anti-human antibodies (NA934 or NA933, respectively;
GE Healthcare, Buckinghamshire, UK). The signals were
detected using enhanced chemiluminescence reagent (GE
Healthcare) followed by exposure to X-ray film.
Cell proliferation assays. Control-B16 and APN-B16 cells
(5 9 103 cells ⁄well) were incubated in 96-well plates, with
100 lL medium per well. After culturing for 1–4 days, 10 lL
of Cell Counting Kit-8 reagent (Dojindo, Kumamoto, Japan)
was added to each well according to the manufacturer’s proto-
col. The absorbance was measured at 450 nm using a micro-
plate reader.
Subcutaneous tumor model. Control-B16 or APN-B16 cells
(1 9 104) were inoculated s.c. into the right flanks of nude
mice. H1299, PC14 or A549 cells (1 9 106) were inoculated
into the right flanks of NOD ⁄SCID mice. Tumor-bearing mice
were injected i.p. with 1 mg ⁄kg MT95-4 or control human
IgG (Sigma) twice per week. The length and width of the
tumors were measured using calipers, and the tumor volume
was calculated using the formula: width2 9 length 9 0.5.(21)
Tail vein metastasis model. Control-B16 or APN-B16
(2 9 105) cells were injected into nude mice through the tail
vein. H1299 cells (1 9 106) were injected into NOD ⁄SCID
mice. Tumor-bearing mice were injected i.p. with 1 mg ⁄kg
MT95-4 or control human IgG (Sigma) twice per week.
Evaluation of microvessel density in subcutaneous
tumors. Frozen sections of subcutaneous tumors were incu-
bated with rat polyclonal antibodies against mouse CD31
(550274; BD Biosciences) and then reacted for 30 min with a
biotinylated rabbit anti-rat IgG antibody (Vector Laboratories,
Burlingame, CA, USA). The immunoreaction was amplified
with a Vectastain ABC Kit (Vector Laboratories) and visual-
ized by incubation with a 3, 3-diaminobenzidine solution act-
ing as a chromogen. The sections were then counterstained
with hematoxylin and dehydrated. Images were captured using
a microscope at a magnification of 200 9 (model BZ-9000;
Keyence), and the area of CD31-positive vessel-like structures
was measured in five random microscopic fields per section
using Dynamic Cell Count software (BZ-HIC; Keyence).
Statistical analysis. Statistical analyses were performed using
Prism 5 (GraphPad software, San Diego, CA, USA). All the
results are expressed as means  SEM. Differences between
the groups were evaluated using Student’s t-tests or Mann–
Whitney U-tests. Differences with P-values of < 0.05 were
considered statistically significant.
Results
A fully humanized monoclonal antibody (MT95-4) recognized
APN ⁄CD13 and inhibited invasion and aminopeptidase activity in
HT1080 cells in vitro. By immunizing KM mice with HT1080
fibrosarcoma cells abundantly expressing APN ⁄CD13, we
established a fully humanized monoclonal antibody, MT95-4,
which had inhibitory effects against aminopeptidase activity.
To verify the specificity of MT95-4, western blotting analysis
was performed using HT1080 cell lysates. As shown in Fig-
ure 1a, MT95-4 detected a band at 150 kDa corresponding to
the predicted size of APN ⁄CD13, which coincided with the
band from a commercially available anti-APN ⁄CD13 antibody.
To confirm the selection of MT95-4, we examined the inhib-
itory effects of MT95-4 on the aminopeptidase activity of
HT1080 cells by measuring the level of AMC liberated from
alanine-MCA. As shown in Figure 1b, MT95-4 neutralized the
(a) (b)
(c) (d)
Fig. 3. Effects of MT95-4 on tumor progression in
the tail vein metastasis model and subcutaneous
tumor model using APN-B16 cells. Mice were
administered MT95-4 or control IgG (1 mg ⁄ kg) i.p.
twice a week. (a) Evaluation of the number of lung
surface nodules in the tail vein metastasis model
following injection of APN-B16 cells. The number of
tumor nodules on the lung surface was counted
21 days after injection of APN-B16 cells. Each bar
represents the mean number of nodules from eight
mice per group. *P < 0.05. (b) Evaluation of tumor
volume in a subcutaneous tumor model using APN-
B16 cells. The sizes of subcutaneous tumors were
measured twice a week for 2 weeks after
inoculation of APN-B16 cells. The data represent
the means ( SEM) from eight mice per group.
*P < 0.05. (c) Evaluation of angiogenesis in
subcutaneous tumors derived from APN-B16 cells.
The area of CD31-positive vessels was measured.
Data represent the means ( SEM) from eight mice
per group. ***P < 0.01. (d) Immunohistochemical
staining for CD31 in a subcutaneous tumor. Scale
bar, 100 lm.
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aminopeptidase activity of HT1080 cells. We then evaluated
whether MT95-4 affected the invasive properties of HT1080
cells using Matrigel invasion chambers. Compared to control
IgG, MT95-4 inhibited the invasion of HT1080 cells (Fig. 1c).
APN ⁄CD13 promoted tumor growth and angiogenesis
in vivo. We established two B16-F1-derived cell lines that dif-
fered in the expression levels of human APN ⁄CD13 (control-
B16 and APN-B16 cells). Quantitative real-time PCR and flow
cytometric analysis revealed that APN-B16 cells expressed
high levels of human APN ⁄CD13, while control-B16 cells did
not (Fig. 2a,b). When the in vitro cell proliferation rates of the
two cell lines were compared, no differences were observed
(data not shown).
Next, to determine whether the expression of human APN
⁄CD13 in murine B16-F1 melanoma cells affected tumor pro-
gression in vivo, control-B16 cells or APN-B16 cells were
injected into nude mice through the tail vein or inoculated s.c.
into right flanks of nude mice. As shown in Figure 2c and d,
mice bearing APN-B16 cells exhibited significantly increased
numbers of lung surface nodules and larger subcutaneous
tumors than mice bearing control-B16 cells. In addition, to
confirm the role of APN ⁄CD13 in tumor angiogenesis, the
degrees of angiogenesis in these subcutaneous tumors were
assessed by immunohistochemical staining with anti-CD31
monoclonal antibodies. The CD31-positive areas in subcutane-
ous tumors derived from APN-B16 cells were larger than those
of tumors derived from control-B16 cells (Fig. 2e,f).
MT95-4 reduced tumor progression and angiogenesis pro-
moted by the expression of human APN ⁄ CD13 in murine B16-F1
melanoma cells. To confirm the neutralizing effect of MT95-4
against APN ⁄CD13 in vivo, we established a tail vein metasta-
sis model and a subcutaneous xenograft model using APN-B16
(a)
(b)
(c)
(d)
(e)
(f)
Fig. 4. Effects of MT95-4 on tumor progression in
the tail vein metastasis model and subcutaneous
tumor model using human lung cancer cells. Mice
were administered MT95-4 or control IgG (1 mg
⁄ kg) i.p. twice a week. (a) Expression levels of APN/
CD13 mRNA in human lung cancer cells analyzed by
real-time PCR. (b) Expression levels of APN ⁄ CD13 on
the surface of human lung cancer cells, as analyzed
by flow cytometry. (c), (f) and (i) Evaluation of
tumor volumes in a subcutaneous tumor model
using H1299 (c), PC14 (f) and A549 (i) cells. The
sizes of subcutaneous tumors were measured once
a week for 5 or 6 weeks after inoculation of tumor
cells. The data represent the means ( SEM) for
eight mice per group. *P < 0.05; NS, not significant.
(d), (g) and (j) Evaluation of angiogenesis in
subcutaneous tumors derived from H1299 (d), PC14
(g) and A549 (j) cells. The area of CD31-positive
vessels was measured. Data represent the means
( SEM) for eight mice per group. ***P < 0.001; NS,
not significant. (e), (h) and (k) Immunohistochemical
staining for CD31 in a subcutaneous tumor. Scale
bar, 100 lm.
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cells and administered MT95-4 (1 mg ⁄kg) i.p. twice per week
in tumor-bearing mice. As shown in Figure 3a and b, adminis-
tration of MT95-4 reduced the number of lung surface nodules
and the size of subcutaneous tumors in mice bearing APN-B16
cells. In addition, the sections of subcutaneous tumors consist-
ing of APN-B16 cells were immunohistochemically stained
with anti-CD31 antibodies, and the areas of CD31-positive
vessels were significantly smaller in the MT95-4-treated group
than in the control group (Fig. 3c,d).
Antitumor and anti-angiogenic effects of MT95-4 were depen-
dent on the expression of APN ⁄CD13 in tumor cells. To further
verify whether the antitumor effects of MT95-4 were associ-
ated with the expression of APN ⁄CD13 in cancer cells, we
administered MT95-4 to mice bearing human lung cancer cells
abundantly or weakly expressing APN ⁄CD13. As shown in
Figure 4a and b, real-time PCR analysis and flow cytometric
analysis revealed that APN ⁄CD13 was abundantly expressed in
H1299 and PC14 cells but weakly expressed in A549 cells.
Thus, we established subcutaneous tumor xenografts using
H1299, PC14 and A549 cells in NOD ⁄SCID mice, and MT95-
4 or control IgG was administered i.p. The administration of
MT95-4 reduced tumor volumes in mice bearing H1299 and
PC14 cells (Fig. 4c,f) but not in mice bearing A549 cells
(Fig. 4i). Moreover, the degree of angiogenesis in subcutane-
ous tumors derived from H1299 and PC14 cells was lower in
the MT95-4-treated group than in the control group (Fig. 4d,g);
however, there were no differences in the degree of angiogenesis
between MT95-4-treated and control IgG-treated mice bearing
tumors derived from A549 cells (Fig. 4j).
Discussion
In the present study, we established a fully humanized mono-
clonal antibody, MT95-4, that had the potential to neutralize
human APN ⁄CD13 activity. We also established two murine
melanoma B16-F1-derived cell lines; one exhibited abundant
expression of human APN ⁄CD13, while the other did not
exhibit expression of human APN ⁄CD13. By inoculating these
cells into nude mice, the expression of human APN ⁄CD13 in
murine melanoma cells was shown to promote tumor growth
(g)
(h)
(j)
(k)
(i)
Fig. 4. continued
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and angiogenesis in vivo. Interestingly, MT95-4 was able to
reduce tumor growth and angiogenesis promoted by the
expression of human APN ⁄CD13 in vivo. In addition, we
demonstrated that the ability of MT95-4 to inhibit tumor
growth and angiogenesis was dependent on the expression of
APN ⁄CD13 in tumor cells. In vitro, MT95-4 dose-depen-
dently inhibited the invasive properties of malignant tumor
cells.
The most notable result from the current study was that
we were able to establish a fully humanized monoclonal
antibody, named MT95-4, that could neutralize human APN
⁄CD13 activity. Given that MT95-4 recognized cell surface
APN ⁄CD13, we can speculate that the neutralization of
APN ⁄CD13 activity on the tumor cell surface by MT95-4
reduced tumor progression by inhibiting tumor cell invasion
and angiogenic drive. Interestingly, MT95-4 could not recog-
nize murine APN ⁄CD13 (data not shown) and, thus, did not
inhibit APN ⁄CD13 activity in mouse endothelial cells.
Therefore, the results of the present study suggested that the
APN ⁄CD13 activity of tumor cells promoted angiogenesis
regardless of the APN ⁄CD13 activity of endothelial cells,
and this angiogenic drive from tumor cells was inhibited by
MT95-4.
In the tumor microenvironment, APN ⁄CD13 is expressed in
stromal cells and endothelial cells, and the expression of APN
⁄CD13 in these nonmalignant cells is involved in tumor growth
and angiogenesis.(10,22,23) In the present study, however, we
could not affect the APN ⁄CD13 activity of host murine cells
in the tumor microenvironment because MT95-4 could not
react with mouse APN ⁄CD13. Interestingly, we confirmed that
MT95-4 had the ability to inhibit in vitro tube formation by
human umbilical vein endothelial cells (data not shown).
Therefore, we can speculate that MT95-4 may inhibit APN
⁄CD13 activity not only on tumor cells but also on endothelial
cells in the human tumor microenvironment and may exert
stronger antitumor effects in humans than in our mouse xeno-
graft tumor models. In addition, we were not able to assess
whether MT95-4 has antitumor effects related to antibody-
dependent cellular cytotoxicity and ⁄or complement-dependent
cytotoxicity in the present study. Further experiments are
required to evaluate these points.
APN ⁄CD13 is considered a potential therapeutic target for
the treatment of cancer. Currently, bestatin is clinically used
as an APN ⁄CD13 inhibitor. To the best of our knowledge,
MT95-4 is the first fully humanized monoclonal antibody
against APN ⁄CD13 and has been shown to possess antitu-
mor effects. Given that monoclonal antibodies against vascu-
lar endothelial growth factor or epidermal growth factor
receptor are currently used in the clinical setting,(24–26) we
believe that MT95-4 may be a good candidate for monoclo-
nal antibody-based anticancer therapy. Preparation for the
clinical application of this antibody will begin in the near
future.
In conclusion, we established a fully humanized monoclonal
antibody against APN ⁄CD13 (MT95-4) that inhibited the inva-
sive properties of malignant tumor cells in vitro and prevented
tumor progression and angiogenesis in vivo. These antitumor
effects of MT95-4 were thought to be mediated by the neutral-
ization of APN ⁄CD13 activity at the tumor cell surface. Given
that MT95-4 is a fully humanized antibody and may inhibit
APN ⁄CD13 activity in nonmalignant cells in the tumor micro-
environment, which promote tumor growth, MT95-4 may be a
promising candidate for monoclonal antibody-based anticancer
therapy.
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